REDX Pharma notes election of Lisa Anson to UK BIA Board of Directors

29 Oct 2018

Alderley Park, 29 October 2018 Redx (AIM: REDX), the drug development company focused on cancer and fibrosis, notes the announcement from the UK BioIndustry Association (“BIA”) that Lisa Anson, CEO of the Company, has been elected to serve on the BIA Board of Directors. Her tenure will commence on January 1st 2019 and is for a three year term.


Lisa Anson, CEO of REDX pharma Plc, commented: “I am delighted to be elected to join the BIA Board. I am passionate about the UK Biotech sector, as it is not only the focus for much of the exciting science in the UK, but it is also an important sector supporting the UK economy. Having previously been President of the Association of the British Pharmaceutical Industry (ABPI), I am personally excited at the prospect of working with the BIA to further the Industry.”

 The full text of the BIA press release appears below

For further information, please contact:

Redx Pharma Plc T: +44 1625 469 920
Lisa Anson, Chief Executive Officer
Cantor Fitzgerald Europe (Nominated Advisor & Broker)  T: +44 20 7894 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20 3705 9330
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting T: +44 20 3727 1000
Simon Conway/Stephanie Cuthbert


About Redx Pharma Plc 

Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx’s vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.


If you would like to sign up to regular alerts from Redx Pharma, please follow this link

The full text of the announcement from the BIA:

BIA announces new appointments to the BIA Board at 2018 AGM

26 OCT 18– Following the BIA AGM last week, the Association has announced the new members who have been elected to its Board of Directors. The AGM took place on Thursday 18th October at the QEII Centre as part of the BIA’s annual UK Bioscience Forum and the new board members were voted for by the BIA’s membership in the weeks leading up to the meeting.

There were four corporate places and one ‘other’ member place to fill at the election and the new Board members who will join the Board from January 1st 2019 for a three year term are:


Corporate Board Members:

  • Lisa Anson of Redx Pharma
  • Charlotte Casebourne of Theolytics
  • Oliver Hardick of Puridify
  • Andrew Hotchkiss of Immunocore

Other Board Member:

  • Clare Terlouw of Syncona

BIA CEO Steve Bates said: “These new appointments, emphasise the diversity of the membership we represent. They build on the current strength of the BIA Board and broaden our expertise as the Association continues to take on the challenges presented by Brexit to ensure that our members can grow and be successful.”

Chair of the BIA Board, Dr Jane Osbourn said: “We had an outstanding and comprehensive range of candidates stand for election this year and I would encourage all of those who were not successful this time around to look at standing next year. The BIA Board does an excellent job of representing the membership and leading the Association’s work and I look forward to working with the new Directors over the coming year.”

For more information on the BIA Board – go to the about us section on the BIA website




Ed Sexton, BIA Communications and Media Relations Manager – 0207 630 2196


About the UK BioIndustry Association (BIA)

Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives.


For further information, please go to and